| Structural basis for the synthesis of indirubins as potent and selective inhibitors of glycogen synthase kinase-3 and cyclin-dependent kinases P Polychronopoulos, P Magiatis, AL Skaltsounis, V Myrianthopoulos, ... Journal of medicinal chemistry 47 (4), 935-946, 2004 | 488 | 2004 |
| Roscovitine-derived, dual-specificity inhibitors of cyclin-dependent kinases and casein kinases 1 N Oumata, K Bettayeb, Y Ferandin, L Demange, A Lopez-Giral, ... Journal of medicinal chemistry 51 (17), 5229-5242, 2008 | 200 | 2008 |
| Senescence and senotherapeutics: a new field in cancer therapy V Myrianthopoulos, K Evangelou, PVS Vasileiou, T Cooks, ... Pharmacology & therapeutics 193, 31-49, 2019 | 177 | 2019 |
| Soluble 3′, 6-substituted indirubins with enhanced selectivity toward glycogen synthase kinase-3 alter circadian period K Vougogiannopoulou, Y Ferandin, K Bettayeb, V Myrianthopoulos, ... Journal of medicinal chemistry 51 (20), 6421-6431, 2008 | 134 | 2008 |
| Machine learning and data mining frameworks for predicting drug response in cancer: An overview and a novel in silico screening process based on association rule mining K Vougas, T Sakellaropoulos, A Kotsinas, GRP Foukas, A Ntargaras, ... Pharmacology & therapeutics 203, 107395, 2019 | 111 | 2019 |
| 6-Br-5methylindirubin-3′ oxime (5-Me-6-BIO) targeting the leishmanial glycogen synthase kinase-3 (GSK-3) short form affects cell-cycle progression and induces apoptosis-like … E Xingi, D Smirlis, V Myrianthopoulos, P Magiatis, KM Grant, L Meijer, ... International journal for parasitology 39 (12), 1289-1303, 2009 | 92 | 2009 |
| Novel inverse binding mode of indirubin derivatives yields improved selectivity for DYRK kinases V Myrianthopoulos, M Kritsanida, N Gaboriaud-Kolar, P Magiatis, ... ACS Medicinal Chemistry Letters 4 (1), 22-26, 2013 | 79 | 2013 |
| An integrated computational approach to the phenomenon of potent and selective inhibition of aurora kinases B and C by a series of 7-substituted indirubins V Myrianthopoulos, P Magiatis, Y Ferandin, AL Skaltsounis, L Meijer, ... Journal of medicinal chemistry 50 (17), 4027-4037, 2007 | 73 | 2007 |
| Screening of a composite library of clinically used drugs and well-characterized pharmacological compounds for cystathionine β-synthase inhibition identifies benserazide as a … N Druzhyna, B Szczesny, G Olah, K Módis, A Asimakopoulou, A Pavlidou, ... Pharmacological research 113, 18-37, 2016 | 69 | 2016 |
| Discovery and optimization of a selective ligand for the switch/sucrose nonfermenting-related bromodomains of polybromo protein-1 by the use of virtual screening and hydration … V Myrianthopoulos, N Gaboriaud-Kolar, C Tallant, ML Hall, S Grigoriou, ... Journal of Medicinal Chemistry 59 (19), 8787-8803, 2016 | 56 | 2016 |
| Identification of the substrate recognition and transport pathway in a eukaryotic member of the nucleobase-ascorbate transporter (NAT) family V Kosti, G Lambrinidis, V Myrianthopoulos, G Diallinas, E Mikros PLoS One 7 (7), e41939, 2012 | 53 | 2012 |
| Two new peltogynoids from Acacia nilotica Delile with kinase inhibitory activity A Ahmadu, A Abdulkarim, R Grougnet, V Myrianthopoulos, F Tillequin, ... Planta medica 76 (05), 458-460, 2010 | 53 | 2010 |
| Modeling, substrate docking, and mutational analysis identify residues essential for the function and specificity of a eukaryotic purine-cytosine NCS1 transporter E Krypotou, V Kosti, S Amillis, V Myrianthopoulos, E Mikros, G Diallinas Journal of Biological Chemistry 287 (44), 36792-36803, 2012 | 51 | 2012 |
| Selective cytotoxicity of the herbal substance acteoside against tumor cells and its mechanistic insights C Cheimonidi, P Samara, P Polychronopoulos, EN Tsakiri, T Nikou, ... Redox Biology 16, 169-178, 2018 | 49 | 2018 |
| Tandem virtual screening targeting the SRA domain of UHRF1 identifies a novel chemical tool modulating DNA methylation V Myrianthopoulos, PF Cartron, Z Liutkevičiūtė, S Klimašauskas, ... European journal of medicinal chemistry 114, 390-396, 2016 | 47 | 2016 |
| Exploring and exploiting the systemic effects of deregulated replication licensing TG Petrakis, ES Komseli, M Papaioannou, K Vougas, A Polyzos, ... Seminars in Cancer Biology 37, 3-15, 2016 | 41 | 2016 |
| An inhibitor-driven study for enhancing the selectivity of indirubin derivatives towards leishmanial Glycogen Synthase Kinase-3 over leishmanial cdc2-related protein kinase 3 A Efstathiou, N Gaboriaud-Kolar, D Smirlis, V Myrianthopoulos, ... Parasites & vectors 7, 1-12, 2014 | 41 | 2014 |
| A substrate translocation trajectory in a cytoplasm‐facing topological model of the monocarboxylate/H+ symporter Jen1p I Soares‐Silva, J Sá‐Pessoa, V Myrianthopoulos, E Mikros, M Casal, ... Molecular microbiology 81 (3), 805-817, 2011 | 31 | 2011 |
| Investigating and re-evaluating the role of glycogen synthase kinase 3 beta kinase as a molecular target for cardioprotection by using novel pharmacological inhibitors PE Nikolaou, K Boengler, P Efentakis, K Vouvogiannopoulou, A Zoga, ... Cardiovascular research 115 (7), 1228-1243, 2019 | 30 | 2019 |
| The emerging field of senotherapeutic drugs V Myrianthopoulos Future medicinal chemistry 10 (20), 2369-2372, 2018 | 29 | 2018 |
Emmanuel MikrosProfessor, Pharmaceutical Chemistry, Pharmacy, National and Kapodistrian University of Athens在 pharm.uoa.gr 的电子邮件经过验证
